Abstract
The aims of these studies were to examine the effects of FCC5 (2-carboxamidino-1,2,3,4,10,14b-hexahydrodibenzo (c,f) pyrazino (1,2,-a) azepine HCl), an analogue of mianserin, on immediate type hypersensitivity reactions in-vitro. The actions of FCC5 were examined on the Schultz-Dale reaction of guinea-pig ileum and on histamine and leukotriene release from human- and guinea-pig-sensitized lung fragments. FCC5 (applied topically) was assessed for anti-inflammatory activity in-vivo against phorbol-12-myristate-13-acetate (PMA)-induced oedema in the mouse ear. FCC5 (IC50 = 0.17 microM) was a potent inhibitor of the Schultz-Dale reaction in-vitro, as assessed by a concentration-dependent attenuation of egg albumin-induced contractions of sensitized guinea-pig isolated ileum. Using human and guinea-pig isolated sensitized lung fragments, FCC5 (1-100 microM) attenuated antigen-induced release of sulphidopeptidoleukotrienes and histamine. FCC5 (50 micrograms topically) resembled mianserin and indomethacin in attenuating PMA-induced mouse ear inflammation. These properties together with previously published evidence of long lasting antihistamine properties in-vivo, suggest that FCC5 has therapeutic potential as an anti-allergic agent, ...Continue Reading
References
Apr 1, 1978·Agents and Actions·N Chand, P Eyre
Apr 1, 1992·The Journal of Pharmacy and Pharmacology·I M LeitchR G King
Jun 17, 1992·European Journal of Pharmacology·C Z AmorimB B Vargaftig
Oct 1, 1992·The Journal of Pharmacy and Pharmacology·I M LeitchM P Rechtman
Jan 1, 1992·Clinical and Experimental Pharmacology & Physiology·W R JacksonM Wong
Jan 1, 1990·Agents and Actions·M BouclierC N Hensby
Apr 29, 1986·European Journal of Pharmacology·C Daniels, D M Temple
Apr 1, 1987·The Journal of Pharmacy and Pharmacology·C M TennantD M Temple
Jan 1, 1988·International Archives of Allergy and Applied Immunology·N ChandR D Sofia
Jul 1, 1988·Agents and Actions·U Achterrath-TuckermannB A Peskar
Apr 1, 1988·Agents and Actions·R Grupe, W Pietzsch
Jan 1, 1988·Pharmacology·U Achterrath-TuckermannI Szelenyi
Nov 1, 1986·Agents and Actions·N ChandR D Sofia
Apr 1, 1985·The Journal of Investigative Dermatology·E E OpasJ L Humes
Dec 1, 1985·Agents and Actions·R P CarlsonA J Lewis
Jul 1, 1970·British Journal of Pharmacology·M M Dale, L Zilletti
Apr 8, 1973·Life Sciences. Pt. 2: Biochemistry, General and Molecular Biology·D P EvansD S Thomson
Nov 1, 1974·Clinical Pharmacology and Therapeutics·C G Van Arman
Apr 4, 1974·The New England Journal of Medicine·J A Mills
Nov 1, 1971·European Journal of Pharmacology·B B VargaftigI L Bonta
Jan 1, 1970·Journal of Medicinal Chemistry·W J van der BurgB Vargaftig
Nov 25, 1983·European Journal of Pharmacology·J M HughesD M Temple
Apr 19, 1984·Nature·Y Nishizuka
Jan 1, 1993·Life Sciences·Y Oyanagui, S Sato